Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

Original reporting
Published Nov 6, 2026, 7:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA — source image
Decision brief

The 30-second read

$ASTHNeutralMed
01

Why it matters

The earnings call provides fresh guidance on membership trends, Medicaid headwinds, and premium exposure, which are key inputs for valuation models.

02

Market read

The disclosed guidance and operational updates are likely to influence Astrana Health's stock price in the near term, with mixed signals from Medicaid pressure and growth opportunities.

03

What to watch

The $4.45 B premiums‑at‑risk metric may signal future revenue visibility improvements if ACO contracts perform as expected.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Astrana Health is a U.S. health‑technology company providing value‑based care solutions, with revenue driven by Medicaid, Medicare Advantage, and care‑enablement contracts.

Company-level read

Ticker impact

$ASTHNeutralMedium confidence
Context

Astrana Health disclosed a mid‑single‑digit EBITDA headwind from Medicaid and $4.45 B premiums at risk for 2026, plus new client wins and membership growth guidance during its Q3 2026 earnings call.

Expected impact

potential modest downside as market prices in Medicaid headwinds, offset by upside from care enablement growth and premium‑at‑risk disclosure.

Evidence & confidence

The new guidance numbers are material for valuation, but the net effect is ambiguous, leading to limited directional pressure.

Market effects

Highlights ongoing challenges in Medicaid for health‑tech firms while underscoring growth potential in Medicare Advantage and care‑enablement services.

California and Connecticut market developments may influence regional health‑care providers and insurers.

Limited to U.S. health‑care sector; no broader macro impact.

Counterpoint

Investors could view the Medicaid attrition as temporary and focus on the strong Medicare Advantage margins and care enablement revenue, positioning for upside.

Key entities

  • Brandon Sim

    President and CEO of Astrana Health, provided guidance and commentary.

  • Chan Bhasho

    Chief Operating and Financial Officer, discussed Medicare Advantage risk‑adjustment sweeps.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.